RankAlpha logo

UTHR

Rating neutralAI Memo

United Therapeutics

As of 2026-08-17/Confidence high
Open tickerBack to Memos
Data freshness
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action
neutral
Confidence
high
Horizon
—
Key catalyst
Potential nebulized Tyvaso approval in IPF • 2027-12-31
Base target: $540 / p=50% prob
Biggest risk
Near-term revenue and legacy-product declines indicate competitive and mix pressure. Approval timing is uncertain, management did not reaffirm detailed Tyvaso second-half targets in stored earnings commentary, and margin pressure or weaker physician adoption could delay the growth inflection.
Invalidation
Break below $425 or thesis failure.
What would change my mind?
UTHR has multiple potentially material cardiopulmonary expansion paths, including nebulized Tyvaso in IPF and ralinepag tablets in PAH, while Tyvaso DPI patient metrics remain strong. Stored earnings context also reported modest revenue and adjusted-EPS beats, though the source is secondary.
Research note
Recommendation
neutral
Confidence
high
As of
2026-08-17
Base target
$540
p=50%
Bull target
$650
p=25%
Bear target
$425
p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets
  • Mixed Q2 execution keeps near-term expectations restrained
  • Tyvaso DPI commercial uptake
  • UTHR has multiple potentially material cardiopulmonary expansion paths, including nebulized Tyvaso in IPF and ralinepag tablets in PAH, while Tyvaso DPI patient metrics remain strong.
BearKey bullets
  • CEO Form 4 filings show multiple open-market sales on 2026-08-13 following an option exercise; this is insider-activity context, not evidence of operating performance [#SEC-FORM4-2026-08-14].
  • Competitive pressure in inhaled prostacyclins could continue to offset Tyvaso DPI growth.
  • FDA review, approval timing, and label-expansion execution for nebulized Tyvaso and ralinepag remain uncertain.
WatchKey bullets
  • Potential nebulized Tyvaso approval in IPF

Summary

High-level snapshot

Recommendation
neutral
Model confidence
high
Timeframe
-
Asset
Equity
Trigger
-
Base case: $540 (p=50%)
Target spread vs base: +20% / -21%
Scenario probabilities
Bull Target: $650 (p=25%)Base Target: $540 (p=50%)Bear Target: $425 (p=25%)
Commentary
News tone is mixed: Q2 EPS modestly exceeded estimates in stored earnings context, but revenue declined and core product trends weakened. The same stored context described an initially muted price reaction near the pre-earnings level. Social, options, short-interest, employee-review, and post-print analyst-revision data are unavailable, so this remains a moderate-confidence execution and regulatory monitoring setup.
As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case
UTHR has multiple potentially material cardiopulmonary expansion paths, including nebulized Tyvaso in IPF and ralinepag tablets in PAH, while Tyvaso DPI patient metrics remain strong. Stored earnings context also reported modest revenue and adjusted-EPS beats, though the source is secondary.
Bear Case
Near-term revenue and legacy-product declines indicate competitive and mix pressure. Approval timing is uncertain, management did not reaffirm detailed Tyvaso second-half targets in stored earnings commentary, and margin pressure or weaker physician adoption could delay the growth inflection.

Drivers

Scannable catalysts and supporting factors

  • Mixed Q2 execution keeps near-term expectations restrained
  • Tyvaso DPI commercial uptake

Scenarios

Bull Target (Scenario probability)
$650 / p=25% prob
Base Target (Scenario probability)
$540 / p=50% prob
Bear Target (Scenario probability)
$425 / p=25% prob
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)
52.00
Social Sentiment (7d)
0.00

Events

Other notable items detected

  • EVENT2027-12-31
    Potential nebulized Tyvaso approval in IPF
    United Therapeutics reported submission of an NDA for nebulized Tyvaso in IPF and described potential approval in 2027 as a major growth catalyst. Regulatory timing and approval outcome remain uncertain [#SEC-8K-2026-08-05].
    Prob 55.00% • Move 12.00% • Priced-in 60.00%
  • EVENT2027-12-31
    Potential ralinepag tablet approval in PAH
    Management reported submission of an NDA for ralinepag tablets in PAH and identified potential 2027 approval as another transformative growth opportunity [#SEC-8K-2026-08-05].
    Prob 50.00% • Move 10.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

  • Mixed Q2 execution keeps near-term expectations restrained
    2026-08-05
    Q2 revenue declined 2% year over year to $783.3 million. Tyvaso DPI grew 4%, but nebulized Tyvaso declined 18%, total Tyvaso declined 4%, and Remodulin declined 6%, creating an execution and product-mix overhang [#SEC-8K-2026-08-05].
    Prob 100% • Move -3% • Priced-in 85%

Long-term Catalysts

Months to a year

  • Tyvaso DPI commercial uptake
    2026-12-31
    Management reported record Tyvaso DPI starts, referrals, commercial patients, and total patients at quarter-end, supporting a possible return to sequential portfolio growth if physician adoption continues [#SEC-8K-2026-08-05].
    Prob 65% • Move 8% • Priced-in 55%

Risks

  • CEO Form 4 filings show multiple open-market sales on 2026-08-13 following an option exercise; this is insider-activity context, not evidence of operating performance [#SEC-FORM4-2026-08-14].
  • Competitive pressure in inhaled prostacyclins could continue to offset Tyvaso DPI growth.
  • FDA review, approval timing, and label-expansion execution for nebulized Tyvaso and ralinepag remain uncertain.
  • Nebulized Tyvaso and Remodulin revenue declines may persist, delaying sequential portfolio growth.
  • Operating performance and product mix may remain under pressure if new-product adoption does not accelerate.

Peers

SymbolSummary
GILDLarge commercial biopharma benchmark for portfolio durability and cash generation; scale and portfolio mix make it a loose comparator.
INCYSimilarly sized commercial biopharma comparator useful for execution-sensitive valuation, though not a direct PAH or IPF peer.
REGNLarger commercial-stage biopharma comparator for execution and pipeline optionality; indication overlap with UTHR is limited.

Sources

Internal and external references used in this analysis

  • Model source: RankAlpha Sentiment Codex
  • Analysis date: 2026-08-17